Zoetis (ZTS) Valuation Check After Rare Q1 2026 Miss And Cut To Full Year Guidance

Zoetis (ZTS) is back in focus after its rare Q1 2026 miss on both revenue and earnings, a lowered full year outlook, and a sharp slide in the share price.

See our latest analysis for Zoetis.

The Q1 2026 earnings miss and softer full year guidance have capped an already weak run, with the stock recording a 30 day share price return of down 34.95% and a 1 year total shareholder return of down 51.91%. This points to fading momentum as investors reassess risk.

If recent volatility has you rethinking your watchlist, it could be a good time to look at other opportunities in animal health and biotech by scanning 32 healthcare AI stocks

With Zoetis now trading well below recent levels and some valuation models signaling a large discount, investors are asking a simple question: is this punishment overdone and opening a buying window, or is the market correctly pricing slower growth ahead?

Most Popular Narrative: 49.2% Undervalued

The most followed narrative puts Zoetis' fair value at $151.00, almost double the last close of $76.67, and builds that gap on detailed growth and margin assumptions.

Unmet demand in both companion animal and livestock markets continues to provide significant room for revenue expansion, as millions of pets (especially those with dermatological and chronic pain conditions) remain untreated or under-treated, and growing global protein consumption fuels the need for animal health solutions driving both top-line and recurring revenue growth.

Read the complete narrative.

Curious what earnings path and profit profile sit behind that near 50% discount call? The narrative leans on steady compounding, richer margins, and a valuation multiple that assumes Zoetis keeps its leadership edge.

Result: Fair Value of $151.00 (UNDERVALUED)

Have a read of the narrative in full and understand what's behind the forecasts.

However, the narrative still hinges on competitive pressure in core parasiticide and dermatology franchises, as well as on the OA pain portfolio overcoming safety concerns and slower adoption.

Find out about the key risks to this Zoetis narrative.

Next Steps

With both risks and rewards in the mix, are you comfortable relying on just one narrative, or do you want to pressure test it yourself by weighing the 5 key rewards and 1 important warning sign?

Looking for more investment ideas?

Do not stop your research with a single stock. Widen your opportunity set with focused screens that surface different types of potential ideas in minutes.

• Target potential mispricings by scanning 47 high quality undervalued stocks that combine quality traits with prices that may sit below many investors' radars.
• Strengthen your income watchlist by reviewing 12 dividend fortresses designed to highlight companies with higher yields that could appeal to dividend focused portfolios.
• Prioritize resilience by checking 70 resilient stocks with low risk scores where lower risk scores may suit investors who do not want every holding to be a rollercoaster.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com